BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• TAP Biosystems’ Project to Manufacture 3D Tissue Equivalents - Develops Potential Cell Therapy for Corneal Surface Disease

  January 26, 2012

   · 

  2 min read
• Drug Development

  Vanda Pharmaceuticals, Inc. Release: Initial Clinical Data Reveal Potential of Tasimelteon to Reset the Body Clock in Non-24-Hour Sleep-Wake Disorder

  January 26, 2012

   · 

  6 min read
• AEterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer to be Presented at Upcoming AEterna Zentaris GCS Meeting in San Francisco

  January 26, 2012

   · 

  2 min read
• Drug Development

  Advaxis, Inc. Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer

  January 26, 2012

   · 

  1 min read
• BioCapital

  Biotechnology Industry Organization (BIO) Release: Biotechnology Can Provide Foundation for a U.S. Economy “Built To Last”

  January 26, 2012

   · 

  1 min read
• Pharm Country

  BioReference Laboratories, Inc. to Launch Groundbreaking Solid Tumor Genotyping Test through its GenPath Pharmaceuticals, Inc. Oncology Laboratory

  January 26, 2012

   · 

  1 min read
• Business

  Illumina, Inc. Adopts Stockholder Rights Agreement

  January 26, 2012

   · 

  1 min read
• Business

  Temptime Corporation and Numedis Collaborate to Bring Proprietary Storage and Transportation Technologies that Advance Corneal Transplant Outcomes

  January 26, 2012

   · 

  1 min read
• Pharm Country

  IntelliCell BioSciences Filed Patent Application for its Proprietary Method of Manufacturing Stromal Vascular Fraction Cells

  January 26, 2012

   · 

  1 min read
• Drug Development

  Boehringer Ingelheim Corporation Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib*

  January 26, 2012

   · 

  1 min read